BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Crucell N.V. (CRXL) And Vaxin, Inc. Announce PER.C6 Licensing Agreement


10/19/2005 5:10:08 PM

BIRMINGHAM, Ala., Sept. 13 /PRNewswire/ -- Vaxin Inc., an emerging biotechnology company developing new vaccines for influenza, anthrax, respiratory syncytial virus (RSV) and other diseases, announced today that it has entered into a license agreement with Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq: CRXL). This non-exclusive license agreement allows Vaxin to use Crucell's PER.C6(R) cell line for the development, manufacture and commercialization of its recombinant adenoviral vaccines against certain respiratory viruses.

Under the terms of the agreement, Crucell will receive an upfront payment, annual maintenance fees and royalties on future sales. Further financial details were not disclosed.

"The PER.C6(R) technology is a well-established cell line that is utilized by leading pharmaceutical companies around the world," stated Frank Cano, Ph.D., Vaxin Chairman and Chief Executive Officer. "Several of our products use non-replicating recombinant adenovirus to deliver vaccine antigens to the nose or the skin where they stimulate a protective immune response. The license agreement with Crucell now allows Vaxin to move forward with our portfolio of innovative vaccines."

In humans, the nose and the skin contain an abundance of immune cells that activate protection against disease-causing pathogens. Vaxin's proprietary technology takes advantage of the human immune system's natural defense mechanism and opens up new opportunities for safe and effective vaccines to prevent serious infectious diseases. The company has already completed a Phase I influenza vaccine clinical trial and is preparing to begin a Phase I/II clinical trial for its nasal delivery influenza vaccine. Vaxin's programs also include vaccines to protect against anthrax, RSV and tetanus/diphtheria.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria and West Nile virus. The company's development programs include collaborations with Aventis Pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6(R) technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6(R) technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and CMO partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit http://www.crucell.com/ .

About Vaxin

Vaxin Inc. is an emerging biotechnology company developing vaccines and other biological products utilizing its proprietary technology for non-invasive delivery to the nasal passages and skin. The company's products use non-replicating recombinant adenovirus or inactivated bacterial vectors to deliver vaccine antigens where they stimulate a protective immune response. This method has been tested in proof-of-principle animal studies as well as a Phase I human clinical trial. Initial product development is targeted towards an improved influenza vaccine manufactured in cell culture, and vaccines for anthrax, RSV and tetanus/diphtheria. Earlier stage programs include therapeutic vaccines to address disease targets such as Alzheimer's and cancer. The company has raised more than $15 million in venture capital and government grants.

For more information about Vaxin, please visit our web site http://www.vaxin.com/.

CONTACT: investors, Frank Cano, Ph.D., Chairman and CEO, of Vaxin, Inc., +1-650-949-1750, or cano@vaxin.com; or media, Debra Bannister, +1-530-676-8001, or debban@pacbell.net, for Vaxin, Inc.

Vaxin, Inc.

CONTACT: investors, Frank Cano, Ph.D., Chairman and CEO, of Vaxin, Inc.,+1-650-949-1750, or cano@vaxin.com; or media, Debra Bannister,+1-530-676-8001, or debban@pacbell.net, for Vaxin, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES